BioSpace News Archive

Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration accepted its Biologics License Application for lifileucel for patients with advanced melanoma.

Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter ended March 31, 2023.

Cora Therapeutics, a dynamic life sciences startup based in Toronto, proudly unveils the results of a clinical trial at the Canadian Association of Interventional Radiologists annual meeting in Quebec City.

Genexine announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy for HNSCC in the ASCO.

RELIEF THERAPEUTICS Holding SA announced the Annual General Meeting of shareholders will take place Tues., June 20, 2023 at 9 a.m. CEST at avenue de Sécheron 15 in Geneva, near the Relief Therapeutics offices.

Biophytis SA announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation in France with the French National Authority for Health for the use of Sarconeos [1] in the treatment of adult patients with a severe form of COVID-19, who are at risk of developing a critical form of the disease and for whom therapeutic alternatives are not appropriate.

Castellum, Inc. announces that it is undertaking a cost reduction effort targeting at least $6 million per year in cash and non-cash indirect costs, general and administrative costs, and overhead costs.

BioSyent Inc. released its financial results for the three months ended March 31, 2023.

ProfoundBio announced that dosing in the Phase 1/2 first-in-human trial of PRO1160 has initiated in the US, and the company received approval from National Medical Products Administration to initiate the PRO1160 trial in China.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.